News - Anti-virals

Filter

Current filters:

Anti-virals

Popular Filters

1 to 25 of 423 results

Antiviral gel in condoms to kill HIV approved in Australia

Antiviral gel in condoms to kill HIV approved in Australia

28-07-2014

Australian biotech firm Starpharma says it has achieved a major milestone with the receipt of Conformity…

AnsellAnti-viralsAntibiotics and Infectious diseasesAustraliaBiotechnologyRegulationStarpharmaVivaGel

Indian generic drugmakers set to score from MPP deals on HIV drugs

Indian generic drugmakers set to score from MPP deals on HIV drugs

28-07-2014

Seven new sub-licensing agreements for the manufacture of generic HIV medicines and two new generation…

Anti-viralsGenericsIndiaLicensingPatentsProduction

Gilead beats forecasts as Sovaldi sales soar

Gilead beats forecasts as Sovaldi sales soar

24-07-2014

US anti-virals specialist biotech firm Gilead Sciences has reported surging second-quarter 2014 sales…

Anti-viralsBiotechnologyBusiness FinanceBusiness FinanceChemistryFinancialFixed dose combinationGilead SciencesSovaldiTenofovir

Medicines Patent Pool broadens collaboration with Gilead Sciences

24-07-2014

The Medicines Patent Pool (MPP) has entered into a new licensing agreement with US biotech firm Gilead…

Anti-viralsChinaGenericsGilead SciencesIndiaLicensingProductiontenofovir alafenamide

Celgene's cancer drug Istodax could re-activate dormant HIV and allow it to be detected

Celgene's cancer drug Istodax could re-activate dormant HIV and allow it to be detected

23-07-2014

An anti-cancer drug developed by US biotech company Celgene Corp can re-activate dormant HIV which allows…

Aarhus UniversityAnti-viralsBiotechnologyCelgene Corp.DenmarkHIVHIV/AIDSIsodaxResearchromidepsin

Biotron’s BIT225 reverses HIV-induced impairment of the immune system

23-07-2014

Australian viral disease specialist Biotron presented data at the 20th International AIDS Conference,…

Anti-viralsAntiretroviral drugAustraliaBiotechnologyBiotronBIT225HIVHIV/AIDSImmune systemResearch

Expensive new hepatitis C drugs are worth the investment

Expensive new hepatitis C drugs are worth the investment

21-07-2014

The debate over the high price of new Hepatitis C Virus (HCV) drugs has focused on the price per pill,…

Anti-viralsCVS CaremarkGilead SciencesHepatitis CPharmaceuticalPricingSovaldiUSA

Australian Health Ministers sign on to end HIV transmissions by 2020

Australian Health Ministers sign on to end HIV transmissions by 2020

21-07-2014

All Australian Health Ministers have committed to working towards the virtual elimination of new Australian…

AIDSAnti-viralsAustraliaHealthcareHIV/AIDSPharmaceuticalPoliticsRegulation

Hepatitis C cured in co-infected HIV patients

Hepatitis C cured in co-infected HIV patients

21-07-2014

A multicenter team of researchers report that in a Phase III clinical trial, a combination drug therapy…

Anti-viralsAntiviralsBiotechnologyGilead SciencesHepatitis CResearchRibavirinsofosbuvirSovaldiThe Johns Hopkins University School of MedicineUSA

Médecins Sans Frontières says countries are being priced out of HIV drugs and testing

Médecins Sans Frontières says countries are being priced out of HIV drugs and testing

21-07-2014

International medical humanitarian organization Médecins Sans Frontières has said that high prices…

Anti-viralsAntiretroviral drugHIVHIV/AIDSMSFPharmaceuticalPricing

Sinovac to provide hepatitis A vaccine in Beijing tender to 2016

Sinovac to provide hepatitis A vaccine in Beijing tender to 2016

21-07-2014

China-based Sinovac Biotech has been selected by the Beijing Health Bureau as the sole supplier of inactivated…

Anti-viralsBiotechnologyChinaHealthcareSinovac BiotechVaccination

The price of NOT curing hepatitis C - by Robert Zirkelbach

The price of NOT curing hepatitis C - by Robert Zirkelbach

20-07-2014

Over the past few months, there has been increased focus on the price of a new cure for hepatitis C,…

Anti-viralsBiotechnologyFinancialHealthcareHepatitis CHepatitis CLiver transplantsMedicineTradeUSA

Report: US state governments may spend $55 billion on hepatitis C drugs

Report: US state governments may spend $55 billion on hepatitis C drugs

17-07-2014

State legislatures in the USA will need to find billions in their budgets to purchase costly new hepatitis…

Anti-viralsExpress ScriptsFinancialGilead SciencesHealthcarePharmaceuticalSovaldiUSA

Medicines Patent Pool signs record seven sublicenses to speed HIV generics to developing countries

Medicines Patent Pool signs record seven sublicenses to speed HIV generics to developing countries

17-07-2014

Ahead of the International AIDS Conference in Melbourne, Australia, the Medicines Patent Pool has announced…

Anti-viralsatazanavirBristol-Myers SquibbdolutegravirGenericsGilead SciencesMedicines Patent PoolRoche

Canada approves Pendopharm’s all-oral ribavirin treatment Ibavyr for hepatitis C

Canada approves Pendopharm’s all-oral ribavirin treatment Ibavyr for hepatitis C

16-07-2014

Quebec-based Pendopharm, a division of privately-held Canadian drugmaker Pharmascience, says the regulator…

Anti-viralsBiotechnologyCanadaIbavyrPendopharmPharmascienceRegulation

Drug-treated hepatitis C population to more than double by 2016

Drug-treated hepatitis C population to more than double by 2016

16-07-2014

The hepatitis C virus population is already large, with 2 million diagnosed, chronically infected cases…

Anti-viralsCytokinesDaklinzaDecision Resources GroupEuropeHepatitis CInterferonJapanMarkets & MarketingPharmaceuticalUSA

US Senators press for details on Gilead’s Sovaldi pricing

US Senators press for details on Gilead’s Sovaldi pricing

12-07-2014

Adding to previous criticism from the likes of the medical humanitarian organization Medecins Sans Frontieres…

Anti-viralsBiotechnologyGilead SciencesPoliticsPricingSovaldiUSA

Australia’s TGA clears the way for Gilead’s Sovaldi for hepatitis C

Australia’s TGA clears the way for Gilead’s Sovaldi for hepatitis C

08-07-2014

Australian health care regulator the Therapeutic Goods Administration (TGA) has approved the use of US…

Anti-viralsAustraliaBiotechnologyGilead SciencesRegulationSovaldi

Bristol-Myers hepatitis C treatment Daklinza+Sunvepra OKed in Japan

Bristol-Myers hepatitis C treatment Daklinza+Sunvepra OKed in Japan

07-07-2014

The Japanese Ministry of Health, Labor and Welfare has approved Daklinza (daclatasvir), a potent, pan-genotypic…

Anti-viralsBristol-Myers SquibbDaklinzaDaklinza+SunvepraJapanPharmaceuticalRegulationSunvepra

Isis Pharma earns $1 million GSK milestone on hepatitis B virus program

Isis Pharma earns $1 million GSK milestone on hepatitis B virus program

03-07-2014

USA-based Isis Pharmaceuticals has earned yet another $1 million payment from UK pharma giant GlaxoSmithKline,…

Anti-viralsFinancialGlaxoSmithKlineIsis PharmaceuticalsPharmaceuticalResearch

Gilead submits for approval of hepatitis C drug Sovaldi in Japan

Gilead submits for approval of hepatitis C drug Sovaldi in Japan

27-06-2014

US biotech firm Gilead Sciences revealed this morning it has submitted a New Drug Application to Japan's…

Anti-viralsBiotechnologyGilead SciencesJapanRegulationSovaldi

1 to 25 of 423 results

Back to top